SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Authors:
Reuben J Broom
Reuben J Broom
Auckland City Hospital
Jun Lu
Jun Lu
Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province
China
Paul M Moseley
Paul M Moseley
Nottingham University Hospitals
Baiqu Huang
Baiqu Huang
Northeast Normal University
China
Lili Li
Lili Li
Cancer Research Institute
China
Suling Liu
Suling Liu
University of Michigan
United States

Br J Cancer 2019 Apr 28;120(7):728-745. Epub 2019 Feb 28.

The Institute of Genetics and Cytology, Northeast Normal University, Changchun, China.

Background: SHON nuclear expression (SHON-Nuc) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT).

Methods: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamoxifen treatment. Prognostic significance of SHON and its relationship with the clinical outcome of treatments were analysed.

Results: As previously reported, SHON-Nuc in high risk/ERα patients was significantly associated with a 48% death risk reduction after exclusive adjuvant tamoxifen treatment compared with SHON-Nuc [HR (95% CI) = 0.52 (0.34-0.78), p = 0.002]. Meanwhile, in ERα patients treated with adjuvant ACT, SHON cytoplasmic expression (SHON-Cyto) was significantly associated with a 50% death risk reduction compared with SHON-Cyto [HR (95% CI) = 0.50 (0.34-0.73), p = 0.0003]. Moreover, in patients received Neo-ACT, SHON-Nuc or SHON-Cyto was associated with an increased pathological complete response (pCR) compared with SHON-Nuc [21 vs 4%; OR (95% CI) = 5.88 (1.28-27.03), p = 0.012], or SHON-Cyto [20.5 vs. 4.5%; OR (95% CI) = 5.43 (1.18-25.03), p = 0.017], respectively. After receiving Neo-ACT, patients with SHON-Nuc had a significantly lower distant relapse risk compared to those with SHON-Nuc [HR (95% CI) = 0.41 (0.19-0.87), p = 0.038], whereas SHON-Cyto patients had a significantly higher distant relapse risk compared to SHON-Cyto patients [HR (95% CI) = 4.63 (1.05-20.39), p = 0.043]. Furthermore, multivariate Cox regression analyses revealed that SHON-Cyto was independently associated with a higher risk of distant relapse after Neo-ACT and 5-year tamoxifen treatment [HR (95% CI) = 5.08 (1.13-44.52), p = 0.037]. The interaction term between ERα status and SHON-Nuc (p = 0.005), and between SHON-Nuc and tamoxifen therapy (p = 0.007), were both statistically significant.

Conclusion: SHON-Nuce in tumours predicts response to tamoxifen in ERα BC while SHON-Cyto predicts response to ACT.

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0405-x
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0405-xDOI Listing
April 2019
6 Reads
4.836 Impact Factor

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
March 2, 2019, 5:36 am EST
twitter
Twitter:
March 2, 2019, 5:36 am EST
twitter
Twitter:
March 1, 2019, 2:54 pm EST
twitter
Twitter:
March 1, 2019, 11:53 am EST

Publication Analysis

Top Keywords

tamoxifen treatment
16
relapse risk
12
adjuvant tamoxifen
12
predicts response
12
compared shon-nuc
12
distant relapse
12
shon expression
12
shon-nuc
9
anthracycline-based combination
8
combination chemotherapy
8
risk reduction
8
compared shon-cyto
8
risk compared
8
death risk
8
tamoxifen
8
breast cancer
8
shon-cyto associated
8
tamoxifen therapy
8
patients received
8
shon-cyto
8

References

(Supplied by CrossRef)
Article in Nat. Rev. Clin. Oncol.
D Zardavas et al.
Nat. Rev. Clin. Oncol. 2015
Article in Lancet
R Peto et al.
Lancet 2012

AM Florea et al.
2011
Article in Breast Cancer Res
PE Colombo et al.
Breast Cancer Res 2011
Article in Cell Cycle
P Borst et al.
Cell Cycle 2010
Article in Cancer Res.
Y Jung et al.
Cancer Res. 2013
Article in Int J. Cancer
L Li et al.
Int J. Cancer 2015
Article in Int J. Cancer
DM Abd El-Rehim et al.
Int J. Cancer 2005
Article in Lancet Oncol.
TM Abdel-Fatah et al.
Lancet Oncol. 2016
Article in J. Pathol. Clin. Res
AR Green et al.
J. Pathol. Clin. Res 2016

Similar Publications